Medtronic (NYSE:MDT) Price Target Raised to $100.00

Medtronic (NYSE:MDT) had its price target increased by BTIG Research from $91.00 to $100.00 in a report issued on Tuesday, Marketbeat.com reports. The firm currently has a buy rating on the medical technology company’s stock.

Other analysts have also issued reports about the company. Rothschild & Co Redburn decreased their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. Robert W. Baird cut their target price on Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Medtronic in a report on Tuesday, August 18th. UBS Group upgraded Medtronic from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $100.00 in a research report on Tuesday, July 28th. Finally, Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Nineteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $103.92.

Medtronic Stock Up 0.7%

Medtronic stock opened at $92.87 on Tuesday. Medtronic has a 1-year low of $73.31 and a 1-year high of $106.33. The firm has a market capitalization of $118.87 billion, a price-to-earnings ratio of 22.87, a P/E/G ratio of 2.16 and a beta of 0.56. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The firm has a 50 day simple moving average of $86.52 and a 200 day simple moving average of $85.31.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The firm had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. The business’s quarterly revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts predict that Medtronic will post 5.95 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 4,189 shares of Medtronic stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Medtronic

A number of large investors have recently added to or reduced their stakes in MDT. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Medtronic in the 2nd quarter worth approximately $4,091,000. First Eagle Investment Management LLC grew its position in Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock valued at $1,078,321,000 after acquiring an additional 3,739,288 shares during the last quarter. California State Teachers Retirement System grew its position in Medtronic by 7,655.7% during the second quarter. California State Teachers Retirement System now owns 158,124,578 shares of the medical technology company’s stock valued at $12,370,086,000 after acquiring an additional 156,085,748 shares during the last quarter. Studio Investment Management LLC raised its stake in shares of Medtronic by 15.8% during the second quarter. Studio Investment Management LLC now owns 16,289 shares of the medical technology company’s stock worth $1,286,000 after acquiring an additional 2,221 shares in the last quarter. Finally, VELA Investment Management LLC lifted its holdings in shares of Medtronic by 15.7% in the 2nd quarter. VELA Investment Management LLC now owns 7,734 shares of the medical technology company’s stock worth $605,000 after acquiring an additional 1,048 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal first-quarter results exceeded expectations, with adjusted EPS of $1.45 versus the $1.39 consensus and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, while management raised its fiscal 2027 outlook to approximately $5.94-$6.00 in EPS. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
• Positive Sentiment: Analysts responded favorably to the earnings beat and raised guidance. RBC reaffirmed its Outperform rating with a $118 price target, while TD Cowen maintained a Buy rating; other firms also increased their targets. Medtronic Analysts Raise Their Forecasts
• Positive Sentiment: Management highlighted broad-based growth across major franchises and newer platforms, including robotics and ablation. Investors view this as evidence that Medtronic’s multiyear growth recovery may be gaining momentum. MDT Earnings Call Focuses on Broad Growth
• Positive Sentiment: A PERSIST addendum study is generating additional real-world evidence for Medtronic’s Inceptiv spinal cord stimulation system, potentially strengthening physician adoption and investor confidence. Medtronic’s PERSIST Study
• Positive Sentiment: Medtronic entered a strategic partnership with Cornerstone Robotics intended to expand global access to robot-assisted surgery, supporting its long-term robotics strategy. Cornerstone Robotics Partnership
• Negative Sentiment: Market strategists warned that Medtronic has become a crowded healthcare-sector trade. The recommendation included using options to bet on a decline, reflecting concern that excessive bullish positioning could limit further gains or trigger a pullback. Crowded Healthcare Stocks

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).